The UK Financial Conduct Authority opens a sandbox environment for stablecoin companies
ChainCatcher news, according to Ledger Insights, the UK Financial Conduct Authority (FCA) has announced the launch of a stablecoin working group as part of its regulatory sandbox program, with the application deadline set for January 18, 2026.
According to Bloomberg, the UK Debt Management Office is exploring the expansion of the UK government bond market, a move that will be related to stablecoin reserves. In a speech yesterday, David Geale of the UK Financial Conduct Authority stated that a "large enterprise" has been included in the sandbox program to test a pound sterling stablecoin for payments. Sandbox participants must ensure that their designs comply with the requirements set out in the FCA's consultation paper published in May. The UK adopts a dual-track approach to stablecoin regulation: the Bank of England regulates systemically important stablecoins for prudential and financial stability purposes, while the FCA is responsible for regulating other stablecoins, as well as overseeing conduct and consumer protection for all stablecoins.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
